Download PDF
Dtsch Med Wochenschr 2009; 134(36): 1765
DOI: 10.1055/s-0029-1234013
Pro & Contra | Commentary
Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Haben Biologika einen Stellenwert bei Kollagenosen? Contra

Do biologicals have a place in the treatment of collagen diseases? ContraM. Fleck1
  • 1Klinik für Rheumatologie /Klinische Immunologie, Asklepios Klinikum Bad Abbach
Further Information

Publication History

Publication Date:
28 August 2009 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Biologika - Kollagenosen

Keywords

biologicals - collagenoses

Literatur

  • 1 [The legal aspects of „off label use” or: Doubtful private prescription].  Internist . 2008;  49 322-327
    Google Scholar
  • 2 Carson K R, Evens A M, Richey E A, Habermann T M, Focosi D, Seymour J F. et al . Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.  Blood. 2009;  113 4834-4840
    Google Scholar
  • 3 Harris H E. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab.  Rheumatology (Oxford). 2008;  47 224-225
    Google Scholar
  • 4 Ramos-Casals M, Brito-Zeron P, Munoz S, Soto M J. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases.  Medicine (Baltimore). 2008;  87 345-364
    Google Scholar

Prof. Dr. Martin Fleck

Klinik und Poliklinik für Innere Medizin I, Universitätsklinikum Regensburg und Klinik für Rheumatologie/Klinische Immunologie, Asklepios Klinikum Bad Abbach

Kaiser-Karl-V.-Allee 3

93077 Bad Abbach

Phone: 09405/18-2221

Fax: 09405/18-2930

Email: m.fleck@asklepios.com

      >